University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Pancreas Cancer Program

FOR PATIENTS:
> UCSF Pancreas Center
> UCSF clinical care for pancreas cancer


Program Leader

temperoMargaret Tempero, MD
Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program;
Professor of Medicine, Division of Hematology and Oncology, UCSF

Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science


Funding Opportunities

 

American Association for Cancer Research Funding Available for All Career Stages [more info]
Deadline: varies

UC Pancreatic Cancer Consortium SPORE Projects  [more info]

  • The UC Pancreatic Cancer Consortium submitted a Specialized Program of Research Excellence (SPORE) application to the NCI in May 2020. While the infrastructure scored highly, reviewers were critical of the projects to varying degrees. The Consortium is planning another submission in September 2021 with new and/or revised projects.

    SPORE projects must be translational with a laboratory component and a human application, and are typically collaborations between basic and clinical researchers. Project budgets are expected to be in the region of $200,000–$250,000/yr for 5 years, although projects on early detection, prevention, or population science can request up to an additional $120,000/yr.

UCPCC Collaborative Pilot Project Award [more info]

  • The UC Pancreatic Cancer Consortium will fund a one-year pilot to encourage collaboration between UC campuses, with the expectation that it will lead to submission of a major collaborative grant such as an NIH P01, multi-PI R01, or similar. One award will be given up to $150,000.

National Pancreas Foundation [more info]
Deadline: January 31, 2021

  • Research Grants: $50,000/1 year. Applicants must be within 10 years of receipt of terminal degree. 

Make a Gift

Make a Gift Pancreatic cancer is the third most common cause of cancer death in the United States. The American Cancer Society estimates that in 2020 about 57,600 people will be newly diagnosed with pancreatic cancer and more than 47,000 people will die from the disease. Pancreatic cancer is a silent killer, as its symptoms are so insidious that most people are not diagnosed until the disease has advanced beyond the stage where surgical resection is possible. Even among surgical candidates, removal of the diseased pancreas and surrounding tissues is rarely curative. To add to this bleak picture, pancreas cancer is also noted for its intrinsic resistance to standard regimens of chemo- and radiotherapy. It is clear that new strategies to prevent, diagnose, and treat pancreas cancer are urgently required.